课题基金 / 基金详情

EVALUATING THE EFFECT OF APREPITANT ON CYCLOPHOSPHAMIDE PHARMACOKINETICS

EVALUATING THE EFFECT OF APREPITANT ON CYCLOPHOSPHAMIDE PHARMACOKINETICS
评估阿瑞吡坦对环磷酰胺药代动力学的影响
批准号：
7625640
负责人：
CELESTE M LINDLEY
金额：
$1.14万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-12-01 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7625640
关键词：
AffectComputer Retrieval of Information on Scientific Projects DatabaseCyclophosphamideDrug KineticsFundingGrantInstitutionLearningPurposeResearchResearch PersonnelResourcesSourceUnited States National Institutes of Healthaprepitantresearch study

项目摘要

项目成果

CELESTE M LINDLEY的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是了解新陈代谢如何影响你体内的环磷酰胺水平。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to learn how aprepitant affects the levels of cyclophosphamide in your body.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CYP2B6 GENOTYPE-PHENOTYPE AND THE INFLUENCE OF SEX AND ETHNICITY
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
VALIDATING BUPROPION AS AN IN VIVO PROBE FOR HUMAN CYTOCHROME P450 2B6